Details for New Drug Application (NDA): 022257
✉ Email this page to a colleague
NDA 022257 describes VALCYTE, which is a drug marketed by Cheplapharm and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the VALCYTE profile page.
The generic ingredient in VALCYTE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
The generic ingredient in VALCYTE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
Summary for 022257
| Tradename: | VALCYTE |
| Applicant: | Cheplapharm |
| Ingredient: | valganciclovir hydrochloride |
| Patents: | 2 |
Pharmacology for NDA: 022257
| Mechanism of Action | DNA Polymerase Inhibitors |
Suppliers and Packaging for NDA: 022257
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALCYTE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 022257 | NDA | H2-Pharma, LLC | 61269-485 | 61269-485-10 | 1 BOTTLE, GLASS in 1 CARTON (61269-485-10) / 100 mL in 1 BOTTLE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SOLUTION;ORAL | Strength | 50MG/ML | ||||
| Approval Date: | Aug 28, 2009 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 11, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Dec 11, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
